Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06722235 · ClinicalTrials.gov registry record · Phase 3
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
A Phase 3 study of Immune Thrombocytopenic Purpura (ITP), sponsored by Takeda.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 171
- Enrollment target
- 20
- Study locations
NCT06722235: Recruiting Phase 3 study of Immune Thrombocytopenic Purpura (ITP), sponsored by Takeda.
NCT06722235 is a Phase 3 study of Immune Thrombocytopenic Purpura (ITP) that is actively recruiting participants, run by Takeda. The registered enrollment target is 171 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06722235, a Phase 3 study of Immune Thrombocytopenic Purpura (ITP), is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 171 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it easier to bruise or bleed. The main aim of this study is to learn whether mezagitamab, when given just under the skin (subcutaneously \[SC\]), is effective in keeping the platelet count of adults with ITP stable when compared to a placebo. A placebo looks like medicine but doesn't have any active ingredients in it. The participants will be treated with mezagitamab for up to 6 months. During the study, participants will visit their study clinic several times. Participants who complete the TAK-079-3002 study or do not have any response to study treatment by week 16 (according to study criteria) will be given the opportunity to participate in a continuation study to receive open label mezagitamab (if they are eligible and the site is able to open the continuation study).
Primary Outcome
Durable platelet response is defined as platelet count greater than or equal to (≥)50,000/microliter (μL) on at least 4 of the 6 weekly platelet measurements between Weeks 19 and 24.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Mezagitamab
Study Locations (20)
Massachusetts
- Massachusetts General Hospital - Boston
- University of Massachusetts Chan Medical School - Worcester
North Carolina
- Duke University Hospital - Durham
- East Carolina University - Greenville
Pennsylvania
- Perelman Center for Advanced Medicine (PCAM) Hospital of The University of Pennsylvania Penn Blood Disorders Program - Philadelphia
- Lewis Katz School of Medicine at Temple University - Philadelphia
California
- USC Norris Comprehensive Cancer Center - Keck Medicine of USC - Los Angeles
Colorado
- Rocky Mountain Cancer Center - Denver
District of Columbia
- Georgetown University Medical Center - Lombardi Comprehensive Cancer Center - Washington D.C.
Georgia
- Emory University - Atlanta
Iowa
- The University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2025-02-27 |
| Est. Completion | 2027-12-28 |
| Phase | Phase 3 |
What NCT06722235 shows while recruiting
NCT06722235 is an interventional study that assigns participants to a tested intervention. The registered 171 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Immune Thrombocytopenic Purpura (ITP) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06722235 names 20 study sites across 17 states, led by Massachusetts, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06722235 about?
NCT06722235 is a clinical study titled "A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia". Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it easier to bruise or bleed. The main aim of this study is to learn whether mezagitamab, when given ju...
What is the current status of trial NCT06722235?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 171 participants. The study started on 2025-02-27. Estimated completion is 2027-12-28.
What conditions does trial NCT06722235 study?
This clinical trial studies the following conditions: Immune Thrombocytopenic Purpura (ITP).
What interventions are being tested in trial NCT06722235?
The interventions under investigation include: Placebo (DRUG), Mezagitamab (DRUG).
Who is sponsoring clinical trial NCT06722235?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06722235 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Georgia, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune Thrombocytopenic Purpura (ITP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06722235's enrollment target sits among peer trials
171 1452nd of 2000 higher than 548 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02641145 · 171 participants · NA
Molecular Imaging of Primary Amyloid Cardiomyopathy
- NCT05541029 · 171 participants · NA
Music Listening: A Mechanistic Trial
- NCT05561127 · 171 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel
- NCT05592938 · 171 participants · NA
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI